OSR (OSRH) shares surged 116% amid heavy trading after the company's Vaximm subsidiary said Wednesday the final data from a phase 2a trial showed its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.
Intraday trading volume catapulted to over 75.2 million shares from a daily average of about 1.2 million.
VivoPower International (VVPR) said Wednesday it is in advanced talks with Abu Dhabi-based Energi Holdings on an unsolicited all-cash takeover bid for $120 million. Negotiations between VivoPower's board and Energi are expected to be completed by April 2.
Shares soared 75% as intraday trading volume surged to more than 132 million from a daily average of about 2.7 million.
SurgePays (SURG) said overnight that it expects revenue to exceed $200 million over the next 12 months, compared with sales of $60.9 million reported in 2024.
Shares jumped 61% as intraday trading volume soared to over 63.9 million from a daily average of roughly 295,000.
Price: 3.46, Change: +1.86, Percent Change: +116.44
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。